Jan 5 (Reuters) - Protara Therapeutics Inc TARA.O:
PROTARA THERAPEUTICS RECEIVES BOTH FDA BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS FOR TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS
Source text: ID:nGNX5Wqs5f
Further company coverage: TARA.O
((Reuters.Briefs@thomsonreuters.com;))